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Abstract
Background: Impaired regulatory T cell (Treg) function is thought to contribute to ongoing inflammatory responses in
sarcoidosis, but underlying mechanisms remain unclear. Moreover, it is not known if increased apoptotic susceptibility of
Tregs may contribute to an impaired immunosuppressive function in sarcoidosis. Therefore, the aim of this study is to
analyze proportions, phenotype, survival, and apoptotic susceptibility of Tregs in sarcoidosis.
Methods: Patients with pulmonary sarcoidosis (n = 58) were included at time of diagnosis. Tregs were analyzed in
broncho-alveolar lavage fluid and peripheral blood of patients and healthy controls (HC).
Results: In sarcoidosis patients no evidence was found for a relative deficit of Tregs, neither locally nor systemically.
Rather, increased proportions of circulating Tregs were observed, most prominently in patients developing chronic
disease. Sarcoidosis circulating Tregs displayed adequate expression of FoxP3, CD25 and CTLA4. Remarkably, in sarcoidosis
enhanced CD95 expression on circulating activated CD45RO+ Tregs was observed compared with HC, and proportions of
these cells were significantly increased. Specifically sarcoidosis Tregs - but not Th cells - showed impaired
survival compared with HC. Finally, CD95L-mediated apoptosis was enhanced in sarcoidosis Tregs.
Conclusion: In untreated patients with active pulmonary sarcoidosis, Tregs show impaired survival and enhanced
apoptotic susceptibility towards CD95L. Increased apoptosis likely contributes to the insufficient immunosuppressive
function of sarcoidosis Tregs. Further research into this field will help determine whether improvement of Treg survival
holds a promising new therapeutic approach for chronic sarcoidosis patients.
Background
Sarcoidosis is a multisystem granulomatous disorder of un-
known cause, often affecting the lungs [1]. The disease is
characterized by an exaggerated T helper (Th)1/Th17 re-
sponse upon exposure to one or several antigens in genet-
ically susceptible individuals [2, 3]. Clinical presentation
and disease prognosis vary greatly. Although the majority
of the patients undergo spontaneous resolution, a substan-
tial proportion develops chronic, progressive disease with
need for therapy [1]. Factors that determine granuloma fate
remain to be elucidated [1, 3].
Failure of immune regulatory mechanisms to limit dur-
ation of inflammation has been suggested to contribute to
persisting granulomatous responses in sarcoidosis [4], and
may explain the need for immunosuppressive drugs. Effect-
ive immunosuppressive agents for (chronic) sarcoidosis in-
clude corticosteroids and anti-TNF agents [5]. Interestingly,
these drugs can induce Th cell apoptosis, while sparing or
even inducing regulatory T cell (Treg) proportions and func-
tion [6–10], thereby favoring an anti-inflammatory milieu.
Tregs are an indispensable subset of T cells with strong
immunosuppressive capacities on a wide range of immune
cells, including Th cells, B cells, and antigen presenting
cells [11]. They have a fine sensitivity for immune dynam-
ics, mediated by interleukin(IL)-2 signaling, and can
quickly adjust their numbers and function during immune
challenge [12]. Upon activation, Th cells produce IL-2,
which contributes to Treg proliferation and survival [12].
Appropriate Treg function is required to terminate the im-
mune response after antigen eradication, thus preventing
(redundant) continuing inflammation [12]. Importantly,
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defective Treg function contributes to induction, sustain-
ment or progression of various autoimmune diseases, in-
cluding rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE), but also granulomatous disorders such
as antineutrophil cytoplasmic antibody-associated vasculitis
(AAV) and hypersensitivity pneumonitis (HP) [13–15].
The role of Tregs in the pathogenesis of sarcoidosis re-
mains controversial. An impaired immunosuppressive func-
tion of sarcoidosis peripheral blood (PB) Tregs has been
reported consistently [4, 16–18]. Furthermore, broncho-
alveolar lavage fluid (BALF)-derived Treg suppressive effi-
cacy was found to increase during short-term inhaled
vasoactive intestinal peptide (VIP)-treatment in pulmon-
ary sarcoidosis, which was also associated with amelior-
ation of clinical symptoms (i.e. dyspnea and cough) [19].
Decreased inhibition of Th cell proliferation and cytokine
production by Tregs therefore likely contributes to the on-
going and exaggerated immune responses seen in sarcoid-
osis. Since contradictory results have been reported about
Treg proportions with respect to Th cells in both BALF
and PB of sarcoidosis patients (See for review [3]:), it re-
mains to be determined what mechanism(s) underlies this
impaired immunosuppressive function [3].
Pro- and anti-apoptotic pathways play an important
role in Treg homeostasis [12]. Intriguingly, in sarcoidosis
granulomas and PB increased proportions of activated
(i.e. CD45RO+FoxP3high) proliferating Tregs are found
[4]. The significance of this finding for sarcoidosis patho-
genesis remains unclear, since CD45RO+FoxP3high Tregs
are described to be both more suppressive and more sensi-
tive towards apoptosis in healthy individuals [20]. Although
it has been suggested that increased apoptotic susceptibility
of Tregs may contribute to an impaired immunosuppres-
sive function in sarcoidosis [4], it remains unknown if sur-
vival of patient-derived Tregs is affected.
Therefore, the aim of this study is to analyze pro-
portions, phenotype, survival, and apoptotic suscepti-
bility of sarcoidosis Tregs. Our results demonstrate that in
patients with active pulmonary sarcoidosis, Tregs show im-
paired survival and enhanced apoptotic susceptibility
towards CD95L.
Materials and methods
Study design and subjects
Patients with pulmonary sarcoidosis were included at
time of diagnosis. The diagnosis of sarcoidosis was made
conform the guidelines of the ATS/ERS/WASOG [1].
Exclusion criteria were use of immunomodulatory medi-
cation 3 months prior to study inclusion; respiratory tract
infection 4 weeks prior to study inclusion; concomitant pul-
monary disease (including chronic obstructive pulmonary
disorder and asthma), autoimmune diseases, malignancies,
human immunodeficiency virus seropositivity, pregnancy,
and allergies.
For this study, in total 58 newly diagnosed sarcoidosis
patients donated PB and/or BALF. Due to limitations in
the number of cells isolated per patient, we were not able
to perform all experiments on all patients. Furthermore, 47
healthy controls donated PB and 5 healthy controls under-
went bronchoscopy with BAL for this study.
The Medical Ethical Committee of the Erasmus MC
Rotterdam approved this study. Written informed con-
sent was obtained from every participant before study
inclusion. Further subject characteristics are shown in
Additional file 1: Table S1.
Study materials
Bronchoscopy with BAL and mucosal biopsy was performed
as previously described [21]. BALF cells, mucosal biopsies
and PB were processed as previously described [21].
Flow cytometry staining
BALF cells and PBMCs were stained for extra- and
intracellular markers using the following antibodies:
CD3-APC-eFluor780(SK7), CD4-AF700(OKT4), CD45RO-
FITC(UCHl-1), CD95-APC(DX2), FoxP3-APC(PCH101)
(eBiosciences) and CD25-PE(M-A251), CD25-PE-Cy7(M-
A251), CD127-V450(hIL7R-M21) anti-CTLA-4-BV421(BN
I3) (BD biosciences) and CD45RA-PE-Texas Red(MEM-56)
(Invitrogen). Fixable Aqua Dead Cell Stain kit for 405 nm
(Invitrogen, Molecular Probes) was used as live-dead marker.
Cells were measured on a Flow cytometer LSRII (BD
Biosciences).
Suppression assays
Th cells and Tregs were sorted from PBMCs using a
human CD4+CD25+Regulatory T Cell Isolation Kit (MACS,
Miltenyi Biotec). Th cells were labeled with carboxyfluores-
cein succinimidyl ester (CFSE, Molecular Probes) according
to manufacturer’s protocol. CFSE-labeled Th cells were
stimulated with Anti-Biotin MACSiBead™ Particles (MACS,
Miltenyi Biotec) and co-cultured with unlabeled Tregs. Th
cell division was quantified based on serial halving of CFSE
intensity, using algorithms provided by FlowJo software
(Treestar).
Cytokine measurements in supernatants of co-
cultures were performed using the Bio-Plex Pro Human
Cytokine 17-plex Panel (Biorad), run on a Luminex 100
System (Luminex Corporation), according to manufac-
turer’s protocol.
Survival and apoptosis assays
CD25low-intCD127highTh cells and CD25int-highCD127low-
Tregs were isolated from PBMCs using the BD FACSAria
Cell Sorter (BD Biosciences) and cultured with 20 ng/ml
recombinant human IL-2 (hIL-2; R&D systems). Survival
was determined with DAPI Nucleic Acid Stain (Life
Technologies)-negative cells. To measure Treg survival
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and apoptosis in co-culture with Th cells, CD4+ T cells
were isolated from PBMCs using the human CD4+ T
cell isolation kit (MACS, Miltenyi Biotec), cultured
with 20 ng/ml hIL-2 and examined using the FITC
Annexin V Apoptosis Detection Kit I (BD biosciences).
To assess Treg apoptotic susceptibility, CD4+ T cells
were cultured either with 20 ng/ml hIL-2 or with hIL-2
and 500 ng/ml soluble CD95L (recombinant human
soluble FasL, Enzo Life Sciences).
Statistical analyses
Comparisons were performed using a Mann–Whitney U
test or Wilcoxon matched pairs test. Correlations were
analyzed using Spearman’s rank-order correlation test.
p-values were two sided, and analyses were performed
using IBM SPSS Statistics 21. p < 0.05 was considered
statistically significant.
Results
Increased proportions of circulating Tregs in patients
developing chronic sarcoidosis
Conflicting results have been reported with regard to Treg
proportions in lungs and PB of sarcoidosis patients [3].
Since a relative deficit of Tregs has been suggested to con-
tribute to a persisting granulomatous response in chronic
sarcoidosis [19, 22], we first quantified CD25int-highFox-
P3high Tregs in BALF and PB of active sarcoidosis patients
and healthy controls by flow cytometry. No evidence was
found for a relative deficit of Tregs in BALF of untreated
patients with active sarcoidosis compared with healthy
control BALF (Additional file 2: Figure S1), suggesting an
intact migration of Tregs towards site of inflammation.
Rather, in PB of these patients increased proportions of
CD25int-highFoxP3high Tregs were found (Fig. 1a,b). Inter-
estingly, we determined the disease course of a subgroup
of our study cohort with 2 years clinical follow-up, and
found that in patients developing chronic sarcoidosis, but
not in patients undergoing spontaneous resolution, signifi-
cantly increased Treg proportions were detected at time
of diagnosis, compared with healthy controls (Fig. 1c).
In summary, in untreated patients with active sarcoidosis,
no evidence was found for a relative deficit of Tregs, neither
systemically nor at the site of inflammation. In contrast, sig-
nificantly increased proportions of circulating Tregs were
observed, most prominently in patients developing chronic
disease. These data show that Treg homeostasis is affected
in active sarcoidosis, which could contribute to disease
course.
Circulating Tregs of sarcoidosis patients express adequate
levels of FoxP3, CD25 and CTLA4
Since no numeral deficit of Tregs was found in patients at
time of diagnosis, we questioned whether malfunctioning
of circulating sarcoidosis Tregs is associated with an altered
suppressive phenotype. Therefore, we analyzed circulating
CD25int-highFoxP3high Tregs of active sarcoidosis patients
and healthy controls for expression of forkhead box P3
(FoxP3), CD25 and cytotoxic T lymphocyte antigen 4
(CTLA4) (three proteins pivotal for adequate Treg func-
tion [11]) by flow cytometry.
We confirmed that PB-derived CD25+ Treg suppressive
capacity on autologous Th proliferation and cytokine pro-
duction was significantly less in sarcoidosis compared with
healthy controls (Additional file 3: Figure S2). Circulating
CD25int-highFoxP3high Tregs of patients showed a trend
towards increased expression levels of FoxP3 (Fig. 2a).
Furthermore, CD25 and CTLA4 expression (downstream
molecules of FoxP3) were significantly increased on PB
CD25int-highFoxP3high Tregs of sarcoidosis patients
compared with healthy controls (Fig. 2b,c).
These data suggest that the impaired suppressive cap-
acity of sarcoidosis PB-derived Tregs is not mediated by
decreased expression of FoxP3 and its downstream mole-
cules. Rather, a significant increase in CD25 and CTLA4
expression was found on circulating Tregs from sarcoidosis
patients compared with healthy controls.
Activated CD45RO+ Tregs from sarcoidosis patients highly
express CD95
In healthy individuals, increased CD25 and CTLA4 expres-
sion on circulating Tregs has been associated with an acti-
vated, apoptotic-prone Treg population [20]. Therefore,
increased CD25 and CTLA4 expression on sarcoidosis
PB-derived Tregs could point towards increased apoptosis,
counteracting their functionality. In order to analyze their
apoptotic phenotype, CD45RO and CD95 (FAS; death re-
ceptor) expressing Th cells and Tregs were examined in
PB of healthy controls and patients (Fig. 3a).
Within the PB Treg, but not Th cell population, propor-
tions of CD45RO and CD95 expressing cells were signifi-
cantly increased in sarcoidosis patients compared with
healthy controls (Fig. 3b). The majority of CD45RO+ Tregs
were CD95+ in both patients and controls (Fig. 3a) and
their proportions strongly correlated (p < 0.0001, R = 0.87)
(Fig. 3c). Importantly, surface expression of CD95 was
significantly increased on sarcoidosis CD45RO+ Tregs
compared with healthy control CD45RO+ Tregs, whereas
CD95 expression on CD45RA+ Tregs was low and not dif-
ferent between healthy controls and patients (Fig. 3d).
Altogether, increased proportions of circulating, acti-
vated CD45RO+ Tregs were detected in sarcoidosis.
Importantly, these activated CD45RO+ Tregs highly
express CD95 in patients compared with controls, sug-
gesting altered apoptotic susceptibility.
Impaired survival of sarcoidosis Tregs
We questioned whether sarcoidosis-derived circulating
Tregs would display altered survival. To investigate survival
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of sarcoidosis Th cells and Tregs, we isolated CD25low-
intCD127high Th cells and CD25int-highCD127low Tregs from
PB of patients and healthy controls. Proportions of CD25int-
highFoxP3high Tregs, as measured in the PB of our study
subjects (Fig. 1), strongly correlated with proportions
CD25int-highCD127low Tregs (data not shown). These data
underlined previously published data that CD4+CD25int-
highCD127low (sortable) can be used as surrogate marker for
CD4+CD25int-highFoxP3high Treg isolation and functional
studies [23].
Isolated cells were cultured with IL-2 and spontaneous
survival was measured at 72 hours. Both healthy- and
sarcoidosis-derived Tregs showed decreased survival com-
pared with isolated Th cells (Additional file 4: Figure S3),
confirming that Tregs are an apoptotic-prone population.
Importantly, patient-derived Tregs showed significantly
decreased survival compared with healthy control Tregs
(Fig. 4a). This impaired survival was Treg-specific, since
sarcoidosis-derived Th cells showed comparable survival
to their healthy counterparts (Additional file 4: Figure S3).
The survival defect of sarcoidosis Tregs was not re-
stored when co-cultured with autologous Th cells (Fig. 4b
and c(upper plot)). Moreover, increased proportions of
apoptotic Tregs (annexin V+ and low FSC values) were ob-
served in sarcoidosis (Fig. 4b and c(lower plot)).
These data provide evidence for an impaired survival
of sarcoidosis Tregs, associated with increased apoptotic
susceptibility.
Increased sensitivity of sarcoidosis Tregs towards
CD95L-mediated apoptosis
Since increased CD95 expression was observed on sarcoid-
osis CD45RO+ Tregs (Fig. 3) alongside impaired survival
and increased apoptosis (Fig. 4), we investigated apoptotic
susceptibility of freshly isolated CD4+ T cells towards sol-
uble CD95L. Although both healthy control and sarcoid-
osis Tregs were sensitive towards CD95L-mediated
apoptosis (Fig. 5a/b), CD95L-induced apoptosis was signifi-
cantly enhanced in sarcoidosis Tregs compared with
healthy controls (Fig. 5c).
These data provide evidence for increased susceptibility
of sarcoidosis Tregs towards CD95L-mediated apoptosis.
Discussion
In this study, for the first time, we provide evidence for
an increased apoptotic susceptibility and impaired
A B
C
Fig. 1 Increased proportions of circulating Tregs in patients developing chronic sarcoidosis. Treg proportions were determined in PB of HCs and SRC
patients. a Representative flow cytometry analysis of an HC and SRC patient to determine Tregs in PB. b PB Treg proportions. c Subgroup analyses of PB
Treg proportions at time of diagnosis in patients undergoing disease resolution, or developing (non-) active chronic disease. Statistics: Horizontal lines
indicate the median and significance was determined using a Mann–Whitney U test, ** p < 0.01. PB peripheral blood, HC healthy control, SRC sarcoidosis
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survival of sarcoidosis Tregs. Untreated patients with ac-
tive pulmonary sarcoidosis showed enhanced CD95 ex-
pression levels on circulating activated CD45RO+ Tregs
at time of diagnosis. Additionally, proportions of CD95+
and CD45RO+ circulating Treg were significantly in-
creased. Furthermore, sarcoidosis Tregs were specifically
more susceptible towards CD95L-induced apoptosis com-
pared with healthy controls. Increased apoptosis likely
contributes to the insufficient immunosuppressive func-
tion of sarcoidosis Tregs.
Failure of Treg-mediated immunosuppression is widely
reported in autoimmune diseases [13] as well as granu-
lomatous disorders, including AAV and HP [14, 15]. In sar-
coidosis, impaired immunosuppression by Tregs has been
found both in active and in chronic disease [4, 16–18]. It
has been suggested to contribute to granuloma persistence
[4] and was reported to recover during disease resolution
[18]. Decreased immunosuppression by Tregs on Th cells
may either result from deregulated Tregs (decreased pro-
portions and/or malfunctioning), resistance of Th cells
towards suppression or a combination of both [13]. We
confirmed an impaired immunosuppressive function of PB-
derived Tregs on Th cell proliferation and cytokine produc-
tion. Although our assays cannot exclude that sarcoidosis
Th cells contribute to this phenomenon, a previous study
showed that sarcoidosis Th cells were responsive towards
the suppressive capacity of healthy Tregs [18]. Furthermore,
we did not find evidence for a numeral deficit of Tregs, nei-
ther systemically nor in the lungs of untreated patients with
active pulmonary sarcoidosis at time of diagnosis. Rather,
we and others [4, 18] found increased proportions of circu-
lating Tregs in active sarcoidosis patients.
Importantly, we are the first to report that increased
proportions of circulating Tregs at time of diagnosis are
mainly attributable to patients who develop chronic dis-
ease and not patients who undergo spontaneous reso-
lution. Interestingly, Prasse et al. previously found
significantly decreased Treg proportions in lungs of pa-
tients who develop chronic active disease compared with
controls, but not in patients who undergo spontaneous
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Fig. 2 Adequate expression of FoxP3, CD25 and CTLA4 on sarcoidosis circulating Tregs. FoxP3, CD25 and CTLA4 expression was determined on circulating
CD25int-highFoxP3high Tregs of HC and SRC patients by flow cytometry. a–c. Mean fluorescence intensity of FoxP3 (a), CD25 (b) and CTLA4 (c). Mean
fluorescence intensity was standardized to average expression in healthy control peripheral blood cells. Statistics: Horizontal lines indicate the median and
significance was determined using a Mann–Whitney U test, * p < 0.05 ** p < 0.01. FoxP3 forkhead box P3, CTLA4 cytotoxic T lymphocyte
antigen 4, HC healthy control, SRC sarcoidosis
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resolution [19]. Taken together, these data suggest that
enhanced circulating Treg proportions in sarcoidosis re-
flect impaired migration towards the site of inflamma-
tion. Alternatively, during homeostatic conditions Tregs
rapidly adjust their numbers in response to IL-2 varia-
tions, directly reflecting Th cell activity. Therefore, in
agreement with published findings [12], it is also con-
ceivable that at time of diagnosis in sarcoidosis patients
circulating Treg proportions expand as a result of local
Treg failure, specifically in patients who will develop
chronic sarcoidosis. Therefore, the numbers of circulat-
ing Tregs at the time of diagnosis potentially serve as a
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Fig. 3 Activated CD45RO+ Tregs from sarcoidosis patients highly express CD95. The proportions of CD45RO and CD95 expressing Th cells and
Tregs were determined in PB of HCs and SRC patients. a Representative flow cytometry analysis of an HC and SRC patient to determine the
proportions CD45RO+, CD95high and double positive Tregs (gated on CD3+CD4+CD25int-highCD127low.). b Proportions of CD45RO+ and CD95high
Th cells and Tregs. c Correlation between proportions CD45RO+ Tregs and CD95high Tregs in PB. Open dots represent HC Tregs and closed dots
represent SRC Tregs. d Mean fluorescence intensity of CD95 on CD45RA+ and CD45RO+ Tregs. Statistics: Horizontal lines indicate the median and
significance was determined using a Mann–Whitney U test, * p < 0.05. Correlation was analysed using Spearman’s rank-order correlation test. Regression
line with R and p-value are shown in the plot. Th T helper, CD95 Fas; death receptor, PB peripheral blood, HC healthy control, SRC sarcoidosis
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new biomarker indicating need for immunosuppressive
drugs that restore immune homeostasis. To further ad-
dress this issue prospective studies are warranted.
To the best of our knowledge, it thus far remained un-
clear what mechanism(s) underlies Treg dysfunction in PB
of active sarcoidosis patients. We did not find differences
in FoxP3 expression or diminished expression of its down-
stream molecules CD25 or CTLA4 in circulating Tregs of
sarcoidosis patients. Interestingly, we found that Tregs in
lymph nodes from sarcoidosis patients have reduced
CTLA4 expression compared with controls (Broos et al.,
AJRCCM, in press), indicating that CTLA4 expression
levels are differentially regulated between compartments.
Thus, despite adequate Treg proportions and expression of
FoxP3-downstream effector molecules, sarcoidosis-derived
PB Tregs fail to suppress autologous Th cell responses.
Pro- and anti-apoptotic pathways govern Treg homeo-
stasis [12]. In this study a Treg-specific survival defect was
found in sarcoidosis patients, whereby CD95L-mediated
apoptosis was increased. Although factors determining T
0 102 103 104 105
0
102
103
104
105
6.65
0 102 103 104 105
0
102
103
104
105
4.43
- CD95L + CD95L
F
ox
P
3
CD25
SRC
HC
 = 33,4 % CD95L induced apoptosis
0 102 103 104 105
0
102
103
104
105 5.4
0 102 103 104 105
0
102
103
104
105 12.2
 = 55,7 % CD95L induced apoptosis
A
- CD95L + CD95L
0
5
10
15
20
** *
T
re
g
s
in
cu
lt
u
re
(%
of
C
D
3+
C
D
4+
)
SRCHC
- CD95L + CD95L
B C
HC Tregs SRC Tregs
0
20
40
60 *
%
C
D
95
L
in
du
ce
d
ap
op
to
si
s
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cell sensitivity towards CD95L-mediated apoptosis remain
to be fully elucidated, T cell activation status and CD95 ex-
pression appear critical [24]. Indeed, our data argue that
in sarcoidosis circulating activated CD45RO+ Tregs highly
expressing CD95 compared with control CD45RO+ Tregs,
can contribute to impaired Treg survival.
Our finding that in sarcoidosis Tregs are hypersensi-
tive towards CD95L-mediated apoptosis parallels earlier
findings in SLE [25] and adds to our previously de-
scribed similarities between sarcoidosis and systemic
autoimmune disorders, which include the involvement
of pathogenic IFN-γ-producing Th17 cells [26, 27]. In
SLE increased sensitivity of Tregs towards CD95L-
mediated cell death was proposed to exacerbate the ex-
tent of tissue damage during flares [25]. Increased Treg
apoptosis in sarcoidosis might hamper restoration of the
immune balance and contribute to the development of
(chronic) sarcoidosis. Interestingly, CD95 signaling has
previously been suggested to contribute to chronic sar-
coidosis pathology, since an activating CD95 promotor
polymorphism (−670A) has been associated with disease
severity in Afro-American patients [28]. This -670A vari-
ant in the CD95 gene promotor has also been associated
with SLE and was shown to influence CD95 gene ex-
pression, whereby the A (instead of the G) allele induces
increased CD95 transcription [29]. It is tempting to
speculate that increased transcription of CD95 in sar-
coidosis, mainly affecting activated CD45RO+ Tregs due
to their physiological CD95 expression [24], contributes
to the development of chronic sarcoidosis. Importantly,
increased Treg sensitivity towards CD95L-mediated
apoptosis does not seem to be a general consequence of
chronic inflammation, since it was excluded in multiple
sclerosis and granulomatosis with polyangiitis [30, 31].
Previously it has been suggested that decreased apop-
tosis of antigen-specific T cells might contribute to
granuloma persistence in sarcoidosis [22]. However,
sarcoidosis-derived BALF and PB T cells highly express
CD95 [32, 33] and show signs of apoptosis [34]. Lym-
phocytes infiltrating and surrounding sarcoid granu-
lomas express CD95L [34], and increased amounts of
soluble CD95L are found in BALF and serum of patients
[35]. Most interesting, patients with chronic sarcoidosis
and need for therapy show an increased expression of
CD95 on BALF and PB T cells (including CD45RO on
PB T cells) at time of diagnosis compared with patients
undergoing spontaneous resolution of disease [33]. These
data imply that increased apoptosis of T cells contributes to
ongoing inflammation. However, the role of CD95L-
mediated apoptosis in the homeostasis of pro- and anti-
inflammatory T cell subsets (i.e. Th cells versus Tregs,
respectively) in sarcoidosis thus far remained unclear
[34]. In this study, for the first time, evidence is pro-
vided for a Treg specific survival defect, which can lead
to an imbalance between pro-inflammatory Th cells and
properly functioning anti-inflammatory Tregs, resulting
in on going inflammation.
The anti-TNF agent infliximab is known to induce Treg
functionality in RA [7]. Induction of Treg survival may very
well contribute to its therapeutic effect as observed in pa-
tients with chronic sarcoidosis [5]. Investigation of Treg
proportions present in or around the granulomas, their
functional capacities, and apoptosis susceptibility during
the natural course of disease and in response to therapy
should further unravel the role of Tregs in the development
of chronic sarcoidosis. Research into this field will help
determine whether improvement of Treg survival, e.g.
by other immunosuppressive drugs, such as rapamycin
[36, 37], holds a promising new therapeutic approach
for chronic sarcoidosis patients.
Conclusion
In conclusion, this study is the first to demonstrate a
role for deregulated Treg survival, mediated by CD95-
signaling, in untreated patients with active pulmonary
sarcoidosis. Increased apoptosis likely contributes to the
insufficient immunosuppressive function of sarcoidosis
Tregs. Further research into this field will help deter-
mine whether improvement of Treg survival holds a
promising new therapeutic approach for (chronic)
sarcoidosis patients.
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